BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 45 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q3 2022. The put-call ratio across all filers is 0.11 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,116 | -73.5% | 30,563 | +117.5% | 0.00% | – |
| Q4 2022 | $23,049 | -30.2% | 14,054 | +16.3% | 0.00% | – |
| Q2 2022 | $33,000 | -57.1% | 12,085 | -37.4% | 0.00% | – |
| Q4 2021 | $77,000 | -25.2% | 19,300 | -38.1% | 0.00% | – |
| Q3 2021 | $103,000 | -48.8% | 31,200 | -41.1% | 0.00% | – |
| Q2 2021 | $201,000 | -47.2% | 52,943 | -46.9% | 0.00% | – |
| Q1 2021 | $381,000 | -65.6% | 99,700 | -59.3% | 0.00% | – |
| Q4 2020 | $1,108,000 | -68.7% | 244,833 | +17.0% | 0.00% | -100.0% |
| Q3 2020 | $3,541,000 | +96.8% | 209,300 | +30.4% | 0.00% | +100.0% |
| Q2 2020 | $1,799,000 | +665.5% | 160,453 | +216.6% | 0.00% | – |
| Q1 2020 | $235,000 | – | 50,685 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SABBY MANAGEMENT, LLC | 242,850 | $923,000 | 0.13% |
| ABNER HERRMAN & BROCK LLC | 241,500 | $918,000 | 0.13% |
| Weaver Consulting Group | 48,881 | $186,000 | 0.10% |
| Tibra Equities Europe Ltd | 87,000 | $331,000 | 0.10% |
| Ikarian Capital, LLC | 293,200 | $1,115,000 | 0.09% |
| GSA CAPITAL PARTNERS LLP | 60,238 | $229,000 | 0.03% |
| Ergoteles LLC | 124,329 | $472,000 | 0.01% |
| CFO4Life Group, LLC | 12,003 | $46,000 | 0.01% |
| HighPoint Advisor Group LLC | 17,033 | $65,000 | 0.01% |
| BOOTHBAY FUND MANAGEMENT, LLC | 32,836 | $125,000 | 0.00% |